Enalapril dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
In people, it is a blood pressure and heart failure drug with one of the deepest records in heart medicine for keeping sick hearts alive.
Evidence grade for Enalapril: Strong. The rule: at least two finished studies in people, and at least 1,000 people who took it. The sum on this page: 2 completed trials, 2,822 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 2,822
- Human studies
- 2
- Found nothing
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved (Vasotec, 1985) for high blood pressure and heart failure. Generic enalapril maleate tablets and liquid are sold. The lifespan hint in male mice comes only from a second look at the data using one statistical test (the Gehan test).
5 effects reported, 4 unwanted, 1 wanted, by people using it, not a trial
Goal pages: Ageing and longevity, Heart and circulation
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Enalapril is a cheap blood pressure pill. It also keeps people with failing hearts alive longer. It has been a prescription drug since the 1980s. Some people now talk about it for a longer life, after a mouse study.
What people take it for
- High blood pressure, its main use.
- Heart failure.
- A longer life, which it has never been tested for in people.
What studies in people showed
In people with failing hearts, it saves lives. In 253 people with the worst heart failure, 26 percent died in six months on it. On a dummy pill, 44 percent died. In 2,569 people with heart failure symptoms, deaths fell from 39.7 to 35.2 percent over about three years. But in 4,228 people with a weak heart and no symptoms, it did not clearly cut deaths. No one has tested it in healthy people for a longer life. Now mice. By the mouse program's main test, it did not help. A second look found fewer male mice died young, and the gain faded with age.
What people report
Reports, not study results
The good
- It is cheap, and doctors have forty years of experience with it.
The bad
- Low blood pressure after the first dose. In one heart study, 7 people stopped for it, and none on the dummy pill.
- Cough.
- High potassium and a rise in a kidney blood marker.
- Rarely, dangerous swelling of the face and throat.
Where these come from: The side effects are from the heart trials and drug records on this page. We have no user reports.
My bottom line
This is a real drug that saves lives in heart failure. If your blood pressure is high, get it treated with your doctor. Taking it with a normal heart to live longer is a guess, and it has real side effects.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Enalapril has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Living longer7,050 people · 3 studies · 1 found nothing
- Heart attacks and strokes7,050 people · 3 studies · 1 found nothing
34 of the 36 indexed goals have no study of any kind behind Enalapril
No study in people, animals or cells on this page reports a result for these. That does not prove Enalapril does nothing for them. It does mean anything you have heard about Enalapril and one of these did not come from a study cited here.
Show full evidence
What is Enalapril?
In people, it is a blood pressure and heart failure drug with one of the deepest records in heart medicine for keeping sick hearts alive. None of that is about ageing. In mice, it did not extend lifespan by the NIA program's standard test. A 2024 second look, using a test that counts early deaths more, found a 7 percent gain in typical male lifespan.
Enalapril is an ACE inhibitor, a type of blood pressure pill. It was approved in the 1980s for high blood pressure and heart failure. Tens of millions of people still take it as a cheap generic. It is on this site because the NIA mouse lifespan program tested it, and people in the longevity world cite that test as a win. The record needs stating carefully.
In people, the evidence is about keeping heart failure patients alive, not about healthy people living longer. In the CONSENSUS trial, 253 patients with the worst kind of heart failure got enalapril or a dummy pill. At six months, 26 percent had died on enalapril against 44 percent on the dummy pill. That is 40 percent fewer deaths. All of the lives saved came from slowing the heart failure itself. None came from preventing sudden death. Low blood pressure made 7 enalapril patients stop, and none on the dummy pill. In SOLVD Treatment, 2,569 patients with heart failure symptoms and a weak pumping heart were followed for about 41 months on average. 35.2 percent died on enalapril against 39.7 percent on the dummy pill, a 16 percent lower risk. In SOLVD Prevention, 4,228 people with the same weak pumping heart but no symptoms took part. Deaths were not clearly lower, 8 percent fewer, which could be chance. But the chance of dying or getting heart failure fell 29 percent. So the drug's life-saving effect is real. It shows up in people whose hearts are already failing. In people without symptoms, it did not clearly save lives.
In mice, the NIA lifespan program fed enalapril at 120 ppm from 4 months of age. Typical (median) male lifespan rose 7 percent. By the program's standard test, that could have been chance. Females showed nothing, and the program reported it as a no. In 2024 a second look at all the program's data used the Gehan test, which counts early and midlife deaths more. It found the male effect held up. It also noted that the survival curves did not fit the pattern the standard test assumes. The same second look says the benefit of enalapril, like captopril, is "markedly diminished with advancing age".
Enalapril is an approved prescription drug everywhere this site covers. Generic tablets and a liquid are sold in the US.
How does Enalapril work?
Enalapril is turned into its active form, enalaprilat, in the liver. That blocks an enzyme called ACE. With ACE blocked, the body makes less of two hormones that tighten blood vessels and hold on to salt (angiotensin II and aldosterone). It also keeps more of bradykinin, which relaxes vessels. In people this lowers blood pressure and eases the load on the heart. In heart failure, it slows the gradual stretching of the heart's main pumping chamber. The SOLVD researchers credited that for the lives saved. It also has the known side effects of this drug type: cough, high potassium, a drop in blood pressure after the first dose, and, rarely, dangerous swelling of the face and throat. In mice, the lifespan program picked it as one of several drugs that act on this blood pressure hormone system. That followed reports that blocking ACE makes rodents live longer. Captopril, tested later at 180 ppm, gave a small clear gain in females. Nobody checked whether the male-only signal for enalapril came from blood pressure, kidney protection or something else. The second look itself describes a midlife effect that fades in old age.
What have studies in people found about Enalapril?
Lots for heart failure and blood pressure, none for ageing. Enalapril has been compared with a dummy pill in thousands of people with heart disease. It has been prescribed for forty years. So how well it works in heart failure, and its side effects, are some of the best known of any drug on this site. No trial has tested it for anything to do with ageing in healthy people.
- SOLVD Prevention, 4,228 people with a weak pumping heart but no symptoms: deaths 8 percent lower, small enough to be chance. Getting heart failure was 29 percent less likely.
- SOLVD Treatment, 2,569 patients with heart failure symptoms: 35.2 percent died on enalapril against 39.7 percent on the dummy pill over 3.4 years, a 16 percent lower risk.
- CONSENSUS, 253 patients with the worst (class IV) heart failure: 26 percent died at six months against 44 percent, 40 percent fewer deaths, all from slowing the heart failure itself.
- Side effects across the trials: a drop in blood pressure after the first dose, cough, higher potassium and creatinine (a kidney marker), and rare dangerous face and throat swelling. In CONSENSUS, low blood pressure made 7 of 127 stop on the drug, and none on the dummy pill.
- No trial has given enalapril to people without heart disease to see whether they live longer.
What this does not tell you: Every life saved here was in people whose hearts were failing. The one trial in people without symptoms found no clear effect on deaths. These data say nothing about whether an adult with normal blood pressure would live longer on enalapril. The mouse signal behind the question comes from a second look at old data, in males only. Its own authors say it fades with age.
The state of the research
The National Institute on Aging runs a mouse lifespan program called the Interventions Testing Program. It tests each compound at three labs at the same time: The Jackson Laboratory, the University of Michigan and UT Health San Antonio. The mice are a mixed breed, so a result is less likely to be a quirk of one strain. Males and females are both tested and judged separately. The three labs' results are then pooled. Every result gets published, whether or not the compound worked. It runs on public money from the National Institute on Aging, with no drug company money. Enalapril was fed at 120 ppm from 4 months and reported as a no: a 7 percent gain in typical (median) male lifespan that the standard test could not tell apart from chance, and nothing in females.
Some results on these pages are called "Gehan-only". That is a weaker claim than "made mice live longer", so it needs explaining. The program's standard test counts every death the same. In 2024 a group at UT Health San Antonio went back over all the program's survival data from 2004 to 2022. That covered 132 compound and sex pairs. They used a second test, called the Gehan test. It gives more weight to deaths that happen young and in midlife. Five compounds that failed the standard test passed this one: metformin, enalapril and 17-DMAG in males, and CAPE and green tea extract in females. The authors say this is the pattern you would expect from something that stops mice dying young and then stops helping. In their words, the effects are "limited to midlife and may not be effective at older ages". They did not report any adjustment for running so many tests at once. So a Gehan-only result means fewer mice died young. By old age the groups caught up, and the oldest mice lived no longer.
For enalapril, the male survival curves did not fit the pattern the standard test assumes. That is the technical reason to prefer the Gehan test here, and by that test the male result held up. By the mouse program's own standard, enalapril has not made mice live longer. By the second look, it cut male deaths before midlife. Both are true, and the second is the weaker claim. No money will settle it. Enalapril is a generic that costs pennies, and nobody will pay for a lifespan trial of it in healthy people. Without one, neither benefit nor harm in that group will be measured.
The evidence, in charts
Fig. 1a · how many people
7,050people, across 3 studies in people cited here
| Study | People | Share |
|---|---|---|
| New England Journal of Medicine 1992 | 4,228 | 60% |
| New England Journal of Medicine 1991 | 2,569 | 36% |
| CONSENSUS, New England Journal of Medicine 1987 | 253 | 4% |
One study holds 60% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 5 sources here are studies in people. The rest are not.
- Study in people · done in people360%
- Animal study · done in animals240%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 5 different years, 1987 to 2024, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four countries shown. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- Not on file
- Half-life
- About 11 hoursMedium, 6 to 24 hours
- Chain length
- None on file
Half-life as stated on file: About 11 hours (enalaprilat, effective half-life for accumulation)
No amino acid sequence is on file for Enalapril, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people1987Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
This is one of the clearest survival gains ever shown for a pill. 253 patients with the worst kind of heart failure got enalapril or a dummy pill on top of their usual treatment, and nobody involved knew which. At six months, 26% of the enalapril group had died against 44% on the dummy pill. Every life saved came from slowing the heart failure itself, not from preventing sudden death. Seven people stopped for low blood pressure, and none on the dummy pill.
253 patients with NYHA class IV heart failure, double-blind, enalapril 2.5 to 40 mg a day or placebo on top of conventional therapy. Six-month mortality 26 versus 44 percent (40 percent reduction, p = 0.002); one-year 31 percent reduction; 50 versus 68 deaths overall (27 percent). Entire benefit in progressive heart failure deaths, none in sudden death. Hypotension withdrawals 7 versus 0. Funding not stated in the abstract retrieved.
- Study in people1991Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure (SOLVD Treatment)
In people with symptoms, enalapril kept more of them alive. 2,569 patients with heart failure and a weak pumping heart took enalapril or a dummy for about three and a half years on average. 452 died on enalapril against 510 on the dummy, roughly a sixth fewer deaths. Hospital admissions for heart failure fell further still. A United States government institute ran it, not a drug company. A large trial, and a real but moderate benefit.
2,569 patients with symptomatic heart failure and ejection fraction 0.35 or below, enalapril 2.5 to 20 mg a day or placebo, mean follow-up 41.4 months. Deaths 452 (35.2 percent) versus 510 (39.7 percent), risk reduction 16 percent (95 percent CI 5 to 26, p = 0.0036); death or heart failure hospitalisation 613 versus 736 (26 percent reduction). Run by the US National Heart, Lung, and Blood Institute.
- Study in people1992Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions (SOLVD Prevention)
In people with no symptoms, enalapril did not clearly save lives. 4,228 people with a weak pumping heart but no symptoms took enalapril or a dummy pill for about three years. 313 died on enalapril against 334 on the dummy pill, a gap small enough to be chance. A study this size would likely have found a real survival gain if there was one. It did delay heart failure. For anyone reading enalapril as a longevity drug, this is the result that matters, and it came up empty.
4,228 asymptomatic people with ejection fraction 0.35 or below, mean follow-up 37.4 months. Total mortality 313 versus 334 deaths, risk reduction 8 percent (95 percent CI -8 to 21, p = 0.30), not significant. Death or development of heart failure 630 versus 818 (29 percent reduction, p < 0.001). The null mortality result in people without symptoms is the relevant one for anyone reading enalapril as a longevity drug.
- Animal study2024The Gehan test identifies life-extending compounds overlooked by the log-rank test in the NIA Interventions Testing Program: metformin, enalapril, caffeic acid phenethyl ester, green tea extract, and 17-DMAG
In mice. A second look at 132 comparisons from the NIA mouse lifespan program, 2004 to 2022. Enalapril at 120 ppm from 4 months, 170 treated males against 357 untreated: typical male lifespan rose 7 percent. The standard test said that could be chance. The Gehan test, which counts early deaths more, said it held up. Females showed nothing. No adjustment for running so many tests was reported. The authors say the benefit is limited to midlife. Public NIA money paid for it.
Reanalysis of 132 ITP comparisons from 2004 to 2022. Enalapril 120 ppm from 4 months, 170 treated males against 357 controls: median lifespan +7 percent, log-rank p = 0.22 (not significant), Gehan p = 0.046, proportional hazards assumption violated. No female effect. No multiplicity correction reported. The authors describe the benefit as limited to midlife. NIA funded.
- Animal study2009Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
In mice. This is the NIA mouse lifespan program report best known for its rapamycin result. In the same run, enalapril and CAPE did not clearly make male or female mice live longer by the standard test. Public NIA money paid for it.
The ITP report whose cohort included enalapril and CAPE as agents that did not significantly extend lifespan by log-rank test in either sex, alongside the landmark rapamycin result. NIA funded.
Common questions
Has Enalapril been tested in people?
Yes. 2,822 people given it across 2 completed trials cited here, 0 of which found nothing. In people, it is a blood pressure and heart failure drug with one of the deepest records in heart medicine for keeping sick hearts alive.
What is the Enalapril dosage?
Approved medicine. No human dose established for unlabelled uses. Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose. FDA-approved (Vasotec, 1985) for high blood pressure and heart failure. Generic enalapril maleate tablets and liquid are sold. The lifespan hint in male mice comes only from a second look at the data using one statistical test (the Gehan test).
Is Enalapril FDA-approved?
FDA-approved (Vasotec, 1985) for high blood pressure and heart failure. Generic enalapril maleate tablets and liquid are sold. The lifespan hint in male mice comes only from a second look at the data using one statistical test (the Gehan test).
Did enalapril extend lifespan in the ITP?
Not by the program's standard test. At 120 ppm from 4 months, typical male lifespan rose 7 percent, but that could have been chance. Females showed nothing. A 2024 second look used the Gehan test, which counts early deaths more. It found the male effect held up. It did not adjust for running 132 comparisons at once. The authors describe the effect as limited to midlife.
What does "Gehan-only" mean?
The standard test counts every death the same, and looks for fewer deaths all through life. The Gehan test gives more weight to deaths that happen young and in midlife. A compound that passes Gehan but not the standard test cut early deaths, and then the groups caught up later. It is a real signal. It is a narrower one than "made mice live longer".
Does enalapril reduce mortality in people?
In heart failure, yes, and the effect is large. In the sickest patients, 40 percent fewer died at six months (CONSENSUS). In heart failure with symptoms, 16 percent fewer died over 3.4 years (SOLVD Treatment). In people with a weak heart but no symptoms, deaths were not clearly lower (SOLVD Prevention). No trial has tested it in healthy people for a longer life.
Should a healthy person take enalapril to live longer?
No trial has asked that, so no evidence answers it. What we know: in people without heart failure symptoms, it did not clearly cut deaths. And the drug has real side effects, including low blood pressure, cough, high potassium and rare dangerous swelling of the face and throat. The mouse signal comes from a second look at old data, in males only, and the authors say it fades with age.